Results 21 to 30 of about 11,906,519 (291)

Anti-vascular endothelial growth factor for neovascular glaucoma [PDF]

Cochrane Database of Systematic Reviews, 2020
Neovascular glaucoma (NVG) is a potentially blinding, secondary glaucoma. It is caused by the formation of abnormal new blood vessels, which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) medications are specific inhibitors of the primary mediators of neovascularization ...
Arathi, Simha, Kanza, Aziz, Andrew, Braganza, Lekha, Abraham, Prasanna, Samuel, Kristina B, Lindsley   +5 more
openaire   +4 more sources

Anti-vascular endothelial growth factor in ophthalmology

Indian Journal of Ophthalmology, 2009
Sinha Rajesh, Choudhary Sunil, Sinha Subijoy, Vashisht Nagender, Kumar Chandrashekhar   +4 more
doaj   +2 more sources

Biomarkers for anti‑vascular endothelial growth factor drugs

Oncology Letters, 2022
Angiogenesis is regulated by interactions between vascular endothelial growth factors (VEGFs) and VEGF receptors. VEGF-A, VEGF-D, placental growth factor (PlGF) and plasminogen activator inhibitor-1 (PAI-1) have tumor angiogenic activity. VEGF-A and PAI-1 levels in the blood may impact the activity of bevacizumab, and VEGF-D levels may similarly ...
Kuriyama, Sho, Yamada, Takeshi, Matsuda, Akihisa, Takahashi, Goro, Iwai, Takuma, Takeda, Kohki, Ueda, Koji, Miyasaka, Toshimitsu, Yokoyama, Yasuyuki, Shinji, Seiichi, Sonoda, Hiromichi, Ohta, Ryo, Yonaga, Kazuhide, Kanaka, Shintaro, Yoshida, Hiroshi   +14 more
openaire   +2 more sources

ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY

Retina, 2022
Background/Purpose: Anti–vascular endothelial growth factor therapies have proven effective in treating retinal diseases but come with a high financial burden to the patient and health care system. Biosimilar drugs present an opportunity to decrease the cost of these important ophthalmic medications, and several ophthalmic ...
Kaiser, Peter K., Schmitz-Valckenberg, Marc Steffen, Holz, Frank G.   +2 more
openaire   +2 more sources

Anti-vascular endothelial growth factor for neovascular glaucoma

Cochrane Database of Systematic Reviews, 2023
Neovascular glaucoma (NVG) is a potentially blinding, secondary glaucoma. It is caused by the formation of abnormal new blood vessels, which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) medications are specific inhibitors of the primary mediators of neovascularization ...
Rittiphairoj, Thanitsara, Roberti, Gloria, Michelessi, Manuele   +2 more
openaire   +3 more sources

Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma [PDF]

Journal of Clinical Oncology, 2015
Treatment of glioblastoma (GBM), the most common primary malignant brain tumor in adults, remains a significant unmet need in oncology. Historically, cytotoxic treatments provided little durable benefit, and tumors recurred within several months.
Lu-Emerson, Christine, Duda, Dan G, Emblem, Kyrre E, Taylor, Jennie W, Gerstner, Elizabeth R, Loeffler, Jay S, Batchelor, Tracy T, Jain, Rakesh K   +7 more
openaire   +4 more sources

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy [PDF]

Cochrane Database of Systematic Reviews, 2014
Proliferative diabetic retinopathy (PDR) is a complication of diabetic retinopathy that can cause blindness. Although panretinal photocoagulation (PRP) is the treatment of choice for PDR, it has secondary effects that can affect vision. An alternative treatment such as anti-vascular endothelial growth factor (anti-VEGF), which produces an inhibition of
Martinez-Zapata M. J., Salvador I., Marti-Carvajal A. J., Pijoan J. I., Cordero J. A., Ponomarev D., Kernohan A., Sola I., Virgili G.   +8 more
openaire   +7 more sources

Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro [PDF]

, 2001
Angiogenesis, the formation of a new blood supply, is an essential step in tumorigenesis. Although vascular endothelial growth factor (VEGF) is known to be a very potent angiogenic factor in most solid tumors, little is known about its production and ...
Losa, Marco, Lohrer, P., Gloddek, J., Renner, U., Lohrer, Penny, Uhl, E., Stalla, G., Pagotto, U., Hopfner, Ursula, Renner, Ulrich, Losa, Marc, Losa, M., Pagotto, Uberto, Gloddek, Jutta, Uhl, Eberhard, Stalla, Günter K., Hopfner, U.   +16 more
core   +1 more source

Intraluminal application of vascular endothelial growth factor enhances healing of microvascular anastomosis in a rat model [PDF]

, 2005
Background: Early reconstitution after injury to the endothelium is an important feature for reducing a number of vessel wall pathologies. We investigated the effect of vascular endothelial growth factor ( VEGF) and its impact on the vascular remodeling ...
Hollenberg, S. M., Shakibaei, M., Kossmehl, P., Faramarzi, S., Paul, M., Schulze-Tanzil, G., Infanger, M., Grosse, J., Grimm, D.   +8 more
core   +1 more source

Anti-vascular endothelial growth factor treatment for eye diseases [PDF]

BMJ, 2012
Treatment is clearly effective but important clinical and public health implications ...
Wong, TY, Cheung, N, Lam, DSC
openaire   +4 more sources